Quest Pharmatech (TSE:QPT) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Quest PharmaTech Inc. has refiled its fiscal 2023 financial statements due to a material misstatement in the valuation of OQP Bio bonds, leading to a significant write-down and a non-cash impairment charge. The revised valuation, conducted by an independent third party, reflects a considerably lower fair value for the OQP Bio bonds. Additionally, the company has appointed Mr. Bradley J. Glass as a new director, pending regulatory approval.
For further insights into TSE:QPT stock, check out TipRanks’ Stock Analysis page.